EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Tonabersat enhances temozolomide‐mediated cytotoxicity in glioblastoma by disrupting intercellular connectivity through connexin 43 inhibition

Elena N C Schmidt, Bernd O Evert, Barbara E F Pregler, Ahmad Melhem, Meng-Chun Hsieh, Markus Raspe, Hannah Strobel, Julian Roos, Torsten Pietsch, Patrick Schuss, Pamela Fischer-Posovszky, Mike-Andrew Westhoff und 6 weitere

Molecular Oncology · 2025

DOI: 10.1002/1878-0261.13786 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Oncology, 2025. Verfasst von Elena N C Schmidt und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, University Hospital Bonn, Germany. Hauptthemen laut MEDLINE: Glioblastoma, Connexin 43, Temozolomide, Brain Neoplasms. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Mildred-Scheel School of Oncology (German Cancer Aid), Deutsche Krebshilfe.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glioblastoma cells rely on connexin 43 (Cx43)‐based gap junctions (GJs) for intercellular communication, enabling them to integrate into a widely branched malignant network. Although there are promising prospects for new targeted therapies, the lack of clinically feasible GJ inhibitors has impeded their adoption in clinical practice. In the present study, we investigated tonabersat (TO), a blood–brain‐barrier‐penetrating drug with GJ‐inhibitory properties, in regard to its potential to disassemble intercellular connectivity in glioblastoma networks. Fluorescence‐guided measurements of calcein cell‐to‐cell transfer were used to study functional intercellular connectivity. Specific DNA fragmentation rates of propidium iodide‐stained nuclei were measured as a surrogate readout for cell death using flow cytometry. CRISPR/Cas9‐mediated gene editing of Cx43 served as a validation tool of cellular effects related to Cx43 GJ inhibition. 3′ mRNA sequencing was performed for molecular downstream analysis. We found that TO reduced intercellular GJ‐mediated cytosolic traffic and yielded a significant reduction of tumor microtube (TM) length. TO‐mediated inhibition of cellular tumor networks was accompanied by a synergistic effect for temozolomide‐induced cell death. CRISPR/Cas9 Cx43 ‐knockout revealed similar results, indicating that TO‐mediated inhibitory effects rely on the inhibition of Cx43‐based GJs. Gene set enrichment analyses found that GJ‐mediated synergistic cytotoxic effects were linked to a significant upregulation of cell death signaling pathways. In conclusion, TO disrupts TM‐based network connectivity via GJ inhibition and renders glioblastoma cells more susceptible to cytotoxic therapy. Given its previous use in clinical trials for migraine therapy, TO might harbor the potential of bridging the idea of a GJ‐targeted therapeutic approach from bench to bedside.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaConnexin 43TemozolomideBrain NeoplasmsHumansCell Line, TumorGap JunctionsCell CommunicationDrug SynergismCRISPR-Cas Systems

Stichwörter der Autor:innen

cell deathconnexin 43glioblastomatonabersattumor microtubestumor networks

Substanzen

Connexin 43TemozolomideGJA1 protein, human

Autor:innen und Institutionen

  • Department of Neurosurgery, University Hospital Bonn, Germany.
  • Brain Tumor Translational Research Group, University Hospital Bonn, Germany.
  • Department of Neurology, University Hospital Bonn, Germany.
  • Department of Pediatrics and Adolescent Medicine, University Medical Center Ulm, Germany.
  • Department of Neuropathology, University Hospital Bonn, Germany.
  • German Center for Child and Adolescent Health (DZKJ), partner site Ulm, Germany.

ORCID-Profile: Ulrich Herrlinger, Matthias Schneider, Anna-Laura Potthoff

Förderung

  • Mildred-Scheel School of Oncology (German Cancer Aid)
  • Deutsche Krebshilfe

Zitieren

APA

Schmidt, E. N. C., Evert, B. O., Pregler, B. E. F., Melhem, A., Hsieh, M. C., Raspe, M., Strobel, H., Roos, J., Pietsch, T., Schuss, P., Fischer-Posovszky, P., Westhoff, M. A., Hölzel, M., Herrlinger, U., Vatter, H., Waha, A., Schneider, M., & Potthoff, A. L. (2025). Tonabersat enhances temozolomide‐mediated cytotoxicity in glioblastoma by disrupting intercellular connectivity through connexin 43 inhibition. Molecular Oncology. https://doi.org/10.1002/1878-0261.13786

Vancouver

Schmidt ENC, Evert BO, Pregler BEF, Melhem A, Hsieh MC, Raspe M, et al. Tonabersat enhances temozolomide‐mediated cytotoxicity in glioblastoma by disrupting intercellular connectivity through connexin 43 inhibition. Molecular Oncology. 2025. doi:10.1002/1878-0261.13786

BibTeX
@article{Schmidt2025,
  author = {Schmidt, Elena N C and Evert, Bernd O and Pregler, Barbara E F and Melhem, Ahmad and Hsieh, Meng-Chun and Raspe, Markus and Strobel, Hannah and Roos, Julian and Pietsch, Torsten and Schuss, Patrick and Fischer-Posovszky, Pamela and Westhoff, Mike-Andrew and Hölzel, Michael and Herrlinger, Ulrich and Vatter, Hartmut and Waha, Andreas and Schneider, Matthias and Potthoff, Anna-Laura},
  title = {Tonabersat enhances temozolomide‐mediated cytotoxicity in glioblastoma by disrupting intercellular connectivity through connexin 43 inhibition},
  journal = {Molecular Oncology},
  year = {2025},
  doi = {10.1002/1878-0261.13786}
}
Kostenlos starten →